# reload+after+2024-01-21 06:46:42.833818
address1§99 High Street
address2§30th Floor
city§Boston
state§MA
zip§02110
country§United States
phone§617 300 8460
website§https://praxismedicines.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
fullTimeEmployees§109
companyOfficers§[{'maxAge': 1, 'name': "Mr. Marcio Silva De'Souza M.B.A.", 'age': 44, 'title': 'President, CEO & Director', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 1038518, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Timothy Edwin Kelly', 'age': 49, 'title': 'CFO & Treasurer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 633488, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Steven  Petrou B.Sc. (Hons.), Ph.D.', 'title': 'Co-Founder & Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Lauren  Mastrocola', 'title': 'VP of Finance & Principal Accounting Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Karl  Hansen Ph.D.', 'title': 'Chief Technical Operations Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Alex  Kane', 'title': 'VP of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alex  Nemiroff J.D.', 'age': 44, 'title': 'General Counsel & Secretary', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kelly  McCue', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Alyssa J. S. Wyant', 'age': 48, 'title': 'Chief Regulatory & Quality Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Megan T. Sniecinski', 'age': 41, 'title': 'Chief Business Officer', 'yearBorn': 1982, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§4
boardRisk§7
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§2.838
priceToSalesTrailing12Months§111.73839
currency§USD
dateShortInterest§1702598400
forwardEps§-13.15
pegRatio§0.09
exchange§NMS
quoteType§EQUITY
shortName§Praxis Precision Medicines, Inc
longName§Praxis Precision Medicines, Inc.
firstTradeDateEpochUtc§1602855000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d9e1bd55-646b-3409-879b-a7984b5b3499
gmtOffSetMilliseconds§-18000000
targetHighPrice§270.0
targetLowPrice§16.0
targetMeanPrice§103.92
targetMedianPrice§82.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§6.02
grossMargins§31.50362
ebitdaMargins§0.0
trailingPegRatio§None
